Evidence map›Paper›PMID 39141093›Full record

ReviewPathologie (Heidelberg, Germany)2024

[Endometrial carcinoma: molecular classification in routine pathology].

Udo Siebolts, Birgid Schömig-Markiefka, Janna Siemanowski-Hrach, Sabine Merkelbach-Bruse

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pathologie (Heidelberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Udo SieboltsInstitut für Pathologie, Medizinische Fakultät und Universitätsklinikum Köln, Universität zu Köln, Köln, Deutschland.
Birgid Schömig-MarkiefkaInstitut für Pathologie, Medizinische Fakultät und Universitätsklinikum Köln, Universität zu Köln, Köln, Deutschland.
Janna Siemanowski-HrachInstitut für Pathologie, Medizinische Fakultät und Universitätsklinikum Köln, Universität zu Köln, Köln, Deutschland.
Sabine Merkelbach-BruseInstitut für Pathologie, Medizinische Fakultät und Universitätsklinikum Köln, Universität zu Köln, Köln, Deutschland. sabine.merkelbach-bruse@uk-koeln.de.ORCID http://orcid.org/0000-0002-0312-5760

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The molecular classification of endometrial carcinoma defines four main groups: polymerase‑ɛ(PolE) gene mutated, microsatellite unstable (MSI), p53 abnormal tumors and tumors with no specific molecular profile (NSMP). This classification provides significant insights into the prognosis and therapeutic decisions. Each group exhibits unique genetic profiles identified through immunohistochemistry and molecular diagnostics, enabling personalized treatment. The identification of these molecular signatures necessitates precise analytical methods, selected based on the local circumstances at each site. The approach to molecular classification highlights the critical role of pathology in the diagnosis and emphasizes the necessity of collaboration between the clinic and pathology.

Indexed as

Endometrial NeoplasmsMicrosatellite InstabilityBiomarkers, TumorDNA Polymerase IIFemaleHumansImmunohistochemistryMutationPoly-ADP-Ribose Binding ProteinsTumor Suppressor Protein p53Biomarkers, TumorDNA Polymerase IIPOLE protein, humanPoly-ADP-Ribose Binding ProteinsTumor Suppressor Protein p53Genetic profileImmunohistochemistryMicrosatellitesPOLETP53

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.